DARE
Price
$2.09
Change
+$0.07 (+3.47%)
Updated
Jul 13 closing price
Capitalization
31.31M
24 days until earnings call
Intraday BUY SELL Signals
KLRS
Price
$4.42
Change
-$0.02 (-0.45%)
Updated
Jul 13 closing price
Capitalization
107.07M
37 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DARE vs KLRS

DARE vs KLRS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DARE vs. KLRS commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DARE is a StrongBuy and KLRS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (DARE: $2.09 vs. KLRS: $4.44)
Brand notoriety: DARE and KLRS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DARE: 34% vs. KLRS: 14%
Market capitalization -- DARE: $31.31M vs. KLRS: $107.07M
DARE [@Biotechnology] is valued at $31.31M. KLRS’s [@Biotechnology] market capitalization is $107.07M. The market cap for tickers in the [@Biotechnology] industry ranges from $121.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DARE’s FA Score shows that 0 FA rating(s) are green whileKLRS’s FA Score has 1 green FA rating(s).

  • DARE’s FA Score: 0 green, 5 red.
  • KLRS’s FA Score: 1 green, 4 red.
According to our system of comparison, KLRS is a better buy in the long-term than DARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DARE’s TA Score shows that 5 TA indicator(s) are bullish while KLRS’s TA Score has 5 bullish TA indicator(s).

  • DARE’s TA Score: 5 bullish, 3 bearish.
  • KLRS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, DARE is a better buy in the short-term than KLRS.

Price Growth

DARE (@Biotechnology) experienced а +0.48% price change this week, while KLRS (@Biotechnology) price change was -6.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.21%. For the same industry, the average monthly price growth was +7.25%, and the average quarterly price growth was +1806.27%.

Reported Earning Dates

DARE is expected to report earnings on Aug 06, 2026.

KLRS is expected to report earnings on Aug 19, 2026.

Industries' Descriptions

@Biotechnology (-3.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KLRS($107M) has a higher market cap than DARE($31.3M). DARE YTD gains are higher at: 8.290 vs. KLRS (-47.630). DARE has higher annual earnings (EBITDA): -9.96M vs. KLRS (-44.08M). KLRS has more cash in the bank: 97.2M vs. DARE (18.5M). KLRS has less debt than DARE: KLRS (1.41M) vs DARE (1.61M). DARE has higher revenues than KLRS: DARE (1.16M) vs KLRS (0).
DAREKLRSDARE / KLRS
Capitalization31.3M107M29%
EBITDA-9.96M-44.08M23%
Gain YTD8.290-47.630-17%
P/E Ratio0.10N/A-
Revenue1.16M0-
Total Cash18.5M97.2M19%
Total Debt1.61M1.41M114%
FUNDAMENTALS RATINGS
DARE vs KLRS: Fundamental Ratings
DARE
KLRS
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
16
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
5360
P/E GROWTH RATING
1..100
75100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KLRS's Valuation (16) in the null industry is somewhat better than the same rating for DARE (76) in the Biotechnology industry. This means that KLRS’s stock grew somewhat faster than DARE’s over the last 12 months.

KLRS's Profit vs Risk Rating (100) in the null industry is in the same range as DARE (100) in the Biotechnology industry. This means that KLRS’s stock grew similarly to DARE’s over the last 12 months.

KLRS's SMR Rating (99) in the null industry is in the same range as DARE (100) in the Biotechnology industry. This means that KLRS’s stock grew similarly to DARE’s over the last 12 months.

DARE's Price Growth Rating (53) in the Biotechnology industry is in the same range as KLRS (60) in the null industry. This means that DARE’s stock grew similarly to KLRS’s over the last 12 months.

DARE's P/E Growth Rating (75) in the Biotechnology industry is in the same range as KLRS (100) in the null industry. This means that DARE’s stock grew similarly to KLRS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DAREKLRS
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
72%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 4 days ago
89%
MACD
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 4 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
84%
Advances
ODDS (%)
Bullish Trend 20 days ago
76%
Bullish Trend 12 days ago
85%
Declines
ODDS (%)
Bearish Trend 29 days ago
81%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 4 days ago
86%
Aroon
ODDS (%)
Bearish Trend 4 days ago
75%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
DARE
Daily Signal:
Gain/Loss:
KLRS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
REI1.170.04
+3.54%
Ring Energy
SAP159.972.11
+1.34%
SAP SE
GDS32.800.02
+0.06%
GDS Holdings Limited
PNTG39.86-0.64
-1.58%
Pennant Group (The)
KSCP1.63-0.10
-5.78%
Knightscope Inc

KLRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KLRS has been loosely correlated with PTHS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KLRS jumps, then PTHS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KLRS
1D Price
Change %
KLRS100%
-0.45%
PTHS - KLRS
43%
Loosely correlated
-1.13%
DARE - KLRS
24%
Poorly correlated
+3.47%
AEON - KLRS
23%
Poorly correlated
-33.33%
RIGL - KLRS
23%
Poorly correlated
-2.94%
STTK - KLRS
22%
Poorly correlated
-3.16%
More